{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:25:31Z","timestamp":1788258331360,"version":"build-2803163510"},"reference-count":62,"publisher":"American Veterinary Medical Association (AVMA)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of the study was to evaluate the proportional reporting of neurological adverse events (AEs) associated with feline topical parasiticide products containing macrocyclic lactones (MLs; including eprinomectin) and emodepside by use of postapproval pharmacovigilance data. The intent was to provide veterinarians prescribing these products for their feline patients with the overall comparative context of neurological AE reporting for these products, which have been characterized as substrates for P-glycoprotein transporters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The openFDA and EudraVigilance Veterinary Data Warehouse databases were queried for neurological AEs cumulatively reported through December 31, 2024, for marketed parasiticide products containing MLs (eprinomectin, selamectin, moxidectin) and emodepside for topical administration to cats. The frequencies of neurological AE reporting were compared between products with proportional report rates and disproportionality statistical measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The reporting frequencies of neurological AEs associated with these feline topical parasiticide products were similar. For all products, ataxia was the most frequently reported neurological AE, with proportional report rates ranging from 5.3% to 14.0%. Proportional report rates ranged from 1.7% to 10.7% for convulsion and muscle tremor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An evaluation of pharmacovigilance data from 2 different sources revealed no evidence of greater proportional reporting for neurological AEs specific to the use of eprinomectin-containing products in cats than for other MLs or emodepside.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Relevance<\/jats:title>\n                    <jats:p>These findings supported the conclusion that ML-containing products (including eprinomectin-containing products) and emodepside are comparable in the frequencies and types of neurological AEs associated with feline topical parasiticide products described as substrates for P-glycoprotein transporters.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2460\/javma.25.10.0669","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:03:47Z","timestamp":1767974627000},"page":"559-564","source":"Crossref","is-referenced-by-count":1,"title":["Topically administered macrocyclic lactone products, including eprinomectin, demonstrate comparable neurological safety in cats based on pharmacovigilance data"],"prefix":"10.2460","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-1599","authenticated-orcid":true,"given":"Mark J.","family":"Novotny","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Animal Health, Duluth, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Frana","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Animal Health, St Joseph, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Silva","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Vetmedica GmbH, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Geary","sequence":"additional","affiliation":[{"name":"McGill University, Sainte-Anne-de-Bellevue, QC, Canada"},{"name":"Queen\u2019s University, Belfast, Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"Int J Parasitol Drugs Drug Resist","first-page":"134","article-title":"Moxidectin and the avermectins: consanguinity but not identity","volume":"2","author":"Prichard R","year":"2012","unstructured":"Prichard R, M\u00e9nez C, Lespine A. Moxidectin and the avermectins: consanguinity but not identity. Int J Parasitol Drugs Drug Resist. 2012;2:134-153. doi:10.1016\/j.ijpddr.2012.04.001"},{"issue":"1","key":"ref2","series-title":"J Vet Pharmacol Ther","first-page":"1","article-title":"Canine and feline P-glycoprotein deficiency: what we know and where we need to go","volume":"46","author":"Mealey KL","year":"2023","unstructured":"Mealey KL, Owens JG, Freeman E. Canine and feline P-glycoprotein deficiency: what we know and where we need to go. J Vet Pharmacol Ther. 2023;46(1):1-16. doi:10.1111\/jvp.13102"},{"key":"ref3","series-title":"Committee for Medicinal Products for Veterinary Use Assessment Report for Broadline","year":"2013","unstructured":"Committee for Medicinal Products for Veterinary Use Assessment Report for Broadline. European Medicines Agency; 2013. Report EMA\/674955\/2013. Accessed November 14, 2025. https:\/\/medicines.health.europa.eu\/veterinary\/en\/documents\/download\/17f0c3a8-9717-4c6e-baaa-5b56844ea890"},{"key":"ref4","author":"Broadline Spot-on Solution for Cats: summary of product characteristics. European Medicines Agency","year":"2015","unstructured":"Broadline Spot-on Solution for Cats: summary of product characteristics. European Medicines Agency; 2015. Accessed November 14, 2025. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150413131568\/anx_131568_en.pdf"},{"key":"ref5","article-title":"New animal drug application 141-492","author":"Freedom of information summary: Centragard Transdermal Solution","unstructured":"Freedom of information summary: Centragard Transdermal Solution. New animal drug application 141-492. March 8, 2018. https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/3308"},{"key":"ref6","series-title":"Committee for Medicinal Products for Veterinary Use Assessment Report for NexGard Combo","year":"2020","unstructured":"Committee for Medicinal Products for Veterinary Use Assessment Report for NexGard Combo. European Medicines Agency; 2020. Report EMA\/640861\/2020."},{"key":"ref7","article-title":"NexGard Combo Spot-on Solution for Cats: summary of product characteristics","year":"2021","unstructured":"NexGard Combo Spot-on Solution for Cats: summary of product characteristics. European Medicines Agency; 2021. Accessed November 14, 2025. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230824160163\/anx_160163_en.pdf"},{"key":"ref8","article-title":"New animal drug application 141-570","author":"Corrected freedom of information summary: NexGard Combo","unstructured":"Corrected freedom of information summary: NexGard Combo. New animal drug application 141-570. April 20, 2023. https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/13855"},{"issue":"3","key":"ref9","series-title":"J Vet Pharmacol Ther","first-page":"226","article-title":"Application of eprinomectin-containing parasiticides at label doses causes neurological toxicosis in cats homozygous for ABCB11930_1931del TC","volume":"47","author":"Mealey KL","year":"2024","unstructured":"Mealey KL, Burke NS, Villarino NF, Court MH, Heusser JP. Application of eprinomectin-containing parasiticides at label doses causes neurological toxicosis in cats homozygous for ABCB11930_1931del TC. J Vet Pharmacol Ther. 2024;47(3):226-230. doi:10.1111\/jvp.13431"},{"issue":"11","key":"ref10","series-title":"J Am Vet Med Assoc","first-page":"1414","article-title":"Avermectin-induced neurotoxicity and mortality reported more commonly in cats homozygous for ABCB11930_1931del TC after application of eprinomectin- versus selamectin-containing products","volume":"263","author":"Mealey KL","year":"2025","unstructured":"Mealey KL, Burke NS, Huesser J, Court MH, Cline N, Villarino NF. Avermectin-induced neurotoxicity and mortality reported more commonly in cats homozygous for ABCB11930_1931del TC after application of eprinomectin- versus selamectin-containing products. J Am Vet Med Assoc. 2025;263(11):1414-1419. doi:10.2460\/javma.25.05.0304"},{"key":"ref11","article-title":"DailyMed","author":"Revolution-selamectin solution [USA product label]","unstructured":"Revolution-selamectin solution [USA product label]. DailyMed. Accessed November 14, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8032a1ae-d192-4514-80f1-9a3b50dc2155"},{"key":"ref12","article-title":"DailyMed","author":"Revolution Plus-selamectin and sarolaner solution [USA product label]","unstructured":"Revolution Plus-selamectin and sarolaner solution [USA product label]. DailyMed. Accessed November 14, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=cbcc7b04-f3ab-4f3e-a38f-dcdc313e1b8a"},{"key":"ref13","article-title":"DailyMed","author":"Bravecto Plus-fluralaner and moxidectin solution [USA product label]","unstructured":"Bravecto Plus-fluralaner and moxidectin solution [USA product label]. DailyMed. Accessed November 14, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d9d5ebde-7ff7-4864-b393-fbe77d7a112f"},{"key":"ref14","article-title":"DailyMed","author":"Advantage Multi for Cats-imidacloprid, moxidectin solution [USA product label]","unstructured":"Advantage Multi for Cats-imidacloprid, moxidectin solution [USA product label]. DailyMed. Accessed November 14, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=4acea077-3f1a-4507-ab8c-2f65d9035c97"},{"key":"ref15","series-title":"openFDA","article-title":"Animal and veterinary API endpoints","unstructured":"US FDA. Animal and veterinary API endpoints. openFDA. Accessed November 14, 2025. https:\/\/open.fda.gov\/apis\/animalandveterinary\/event"},{"key":"ref16","article-title":"EudraVigilance Veterinary Data Warehouse","author":"European Medicines Agency","unstructured":"European Medicines Agency. EudraVigilance Veterinary Data Warehouse. Accessed November 14, 2025. https:\/\/www.adrreports.eu\/vet\/en\/search.html"},{"key":"ref17","series-title":"VICH GL24","article-title":"International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; 2007","author":"Pharmacovigilance of veterinary medicinal products: management of adverse event reports (AERs)","unstructured":"Pharmacovigilance of veterinary medicinal products: management of adverse event reports (AERs). International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; 2007. VICH GL24. Accessed November 14, 2025. https:\/\/vichsec.org\/wp-content\/uploads\/2024\/10\/GL24-st7.pdf."},{"key":"ref18","article-title":"European Medicines Agency","author":"Veterinary dictionary for drug regulatory activities (VeDDRA)","unstructured":"Veterinary dictionary for drug regulatory activities (VeDDRA). European Medicines Agency. Accessed November 14, 2025. https:\/\/www.ema.europa.eu\/en\/veterinary-regulatory-overview\/post-authorisation-veterinary-medicines\/pharmacovigilance-veterinary-medicines\/eudravigilance-veterinary#veterinary-dictionary-for-drug-regulatory-activities-veddra-11398"},{"key":"ref19","article-title":"European Medicines Agency","author":"Guidance notes on the use of VeDDRA terminology for reporting suspected adverse events in animals and humans","unstructured":"Guidance notes on the use of VeDDRA terminology for reporting suspected adverse events in animals and humans. European Medicines Agency. EMA\/CVMP\/PhVWP\/288284\/2007-Rev.17. June 12, 2025. Accessed November 14, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guidance-notes-use-veterinary-dictionary-drug-regulatory-activities-veddra-terminology-reporting-suspected-adverse-events-animals-humans-rev17_en.pdf"},{"key":"ref20","article-title":"DailyMed","author":"Profender (2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino- 2,1-aisoquinolin-4-one, emodepside solution; Profender (2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino-2,1-aisoquinolin-4-one, emodepside kit [USA Product label]","unstructured":"Profender (2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino- 2,1-aisoquinolin-4-one, emodepside solution; Profender (2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino-2,1-aisoquinolin-4-one, emodepside kit [USA Product label]. DailyMed. Accessed November 14, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=31f0a4ec-2a29-4de5-971b-633e109b276d"},{"key":"ref21","article-title":"European Medicines Agency; 2025","author":"Profender: summary of product characteristics","unstructured":"Profender: summary of product characteristics. European Medicines Agency; 2025. Accessed November 14, 2025. https:\/\/medicines.health.europa.eu\/veterinary\/en\/documents\/download\/b456ee34-5746-47f1-9727-38adc7bf5802"},{"key":"ref22","series-title":"Veterinary Pharmacovigilance: Adverse Reactions to Veterinary Medicinal Products","first-page":"231","article-title":"Pharmacovigilance in the US - an industry perspective","author":"Hodge TM","year":"2009","unstructured":"Hodge TM. Pharmacovigilance in the US - an industry perspective. In: Woodward KN, ed. Veterinary Pharmacovigilance: Adverse Reactions to Veterinary Medicinal Products. Wiley; 2009:231\u2013285."},{"issue":"5","key":"ref23","series-title":"Expert Opin Drug Saf","first-page":"929","article-title":"The role of data mining in pharmacovigilance","volume":"4","author":"Hauben M","year":"2005","unstructured":"Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929-948. doi:10.1517\/14740338.4.5.929"},{"issue":"11","key":"ref24","series-title":"Drug Saf","first-page":"981","article-title":"Perspectives on the use of data mining in pharmaco-vigilance","volume":"28","author":"Almenoff J","year":"2005","unstructured":"Almenoff J, Tonning JM, Gould AL,  Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 2005;28(11):981-1007. doi:10.2165\/00002018-200528110-00002"},{"issue":"1","key":"ref25","series-title":"J Vet Pharmacol Ther","first-page":"107","article-title":"Evaluation of signal detection algorithms within the Elanco Animal Health Pharmacovigilance database","volume":"44","author":"Novotny MJ","year":"2021","unstructured":"Novotny MJ, Rhodes A, Shields J,  Evaluation of signal detection algorithms within the Elanco Animal Health Pharmacovigilance database. J Vet Pharmacol Ther. 2021;44(1):107-115. doi:10.1111\/jvp.12909"},{"key":"ref26","article-title":"Early experience with adverse drug event signal detection and management at CVM","author":"Walter-Grimm L","unstructured":"Walter-Grimm L, Hugunin K, Palmer LA. Early experience with adverse drug event signal detection and management at CVM. Animal Health Institute Pharmacovigilance Workshop; October 25, 2016; Rockville, MD."},{"issue":"4","key":"ref27","series-title":"Eur J Clin Pharmacol","first-page":"315","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate A","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR,  A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315-321. doi:10.1007\/s002280050466"},{"issue":"6","key":"ref28","series-title":"Drug Saf","first-page":"533","article-title":"A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database","volume":"23","author":"Lindquist M","year":"2000","unstructured":"Lindquist M, St\u00e5hl M, Bate A, Edwards IR, Meyboom RHB. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533-542. doi:10.2165\/00002018-200023060-00004"},{"key":"ref29","article-title":"Signal management: current landscape and considerations for best practices","author":"Wisniewski A","year":"2020","unstructured":"Wisniewski A, Gomez A, Jokinen J,  Signal management: current landscape and considerations for best practices. TransCelerate Biopharma Inc; 2020. Accessed November 14, 2025. https:\/\/www.transceleratebiopharmainc.com\/wp-content\/uploads\/2020\/04\/TransCelerate_ASA_SignalManagementManuscript_April2020.pdf"},{"key":"ref30","article-title":"A Flexible Signal Management Framework for Animal Health Pharmacovigilance","author":"Signal Management Subcommittee of the Animal Health Institute Pharmacovigilance Working Group","year":"2024","unstructured":"Signal Management Subcommittee of the Animal Health Institute Pharmacovigilance Working Group. A Flexible Signal Management Framework for Animal Health Pharmacovigilance. Animal Health Institute; 2024. Accessed November 14, 2025. https:\/\/ahi.org\/wp-content\/uploads\/Flexible-Signal-Management-Framework_2024_FINAL.pdf"},{"key":"ref31","series-title":"J vet Pharmacol Therap","first-page":"429","article-title":"Identification of a nonsense mutation in feline ABCB1","volume":"38","author":"Mealey KL","year":"2015","unstructured":"Mealey KL, Burke NS. Identification of a nonsense mutation in feline ABCB1. J vet Pharmacol Therap. 2015;38:429-433. doi:10.1111\/jvp.12212"},{"key":"ref1","series-title":"Int J Parasitol Drugs Drug Resist","first-page":"134","article-title":"Moxidectin and the avermectins: consanguinity but not identity","volume":"2","author":"Prichard R","year":"2012","unstructured":"Prichard R, M\u00e9nez C, Lespine A. Moxidectin and the avermectins: consanguinity but not identity. Int J Parasitol Drugs Drug Resist. 2012;2:134-153. doi:10.1016\/j.ijpddr.2012.04.001"},{"issue":"1","key":"ref2","series-title":"J Vet Pharmacol Ther","first-page":"1","article-title":"Canine and feline P-glycoprotein deficiency: what we know and where we need to go","volume":"46","author":"Mealey KL","year":"2023","unstructured":"Mealey KL, Owens JG, Freeman E. Canine and feline P-glycoprotein deficiency: what we know and where we need to go. J Vet Pharmacol Ther. 2023;46(1):1-16. doi:10.1111\/jvp.13102"},{"key":"ref3","series-title":"Committee for Medicinal Products for Veterinary Use Assessment Report for Broadline","year":"2013","unstructured":"Committee for Medicinal Products for Veterinary Use Assessment Report for Broadline. European Medicines Agency; 2013. Report EMA\/674955\/2013. Accessed November 14, 2025. https:\/\/medicines.health.europa.eu\/veterinary\/en\/documents\/download\/17f0c3a8-9717-4c6e-baaa-5b56844ea890"},{"key":"ref4","author":"Broadline Spot-on Solution for Cats: summary of product characteristics. European Medicines Agency","year":"2015","unstructured":"Broadline Spot-on Solution for Cats: summary of product characteristics. European Medicines Agency; 2015. Accessed November 14, 2025. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150413131568\/anx_131568_en.pdf"},{"key":"ref5","article-title":"New animal drug application 141-492","author":"Freedom of information summary: Centragard Transdermal Solution","unstructured":"Freedom of information summary: Centragard Transdermal Solution. New animal drug application 141-492. March 8, 2018. https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/3308"},{"key":"ref6","series-title":"Committee for Medicinal Products for Veterinary Use Assessment Report for NexGard Combo","year":"2020","unstructured":"Committee for Medicinal Products for Veterinary Use Assessment Report for NexGard Combo. European Medicines Agency; 2020. Report EMA\/640861\/2020."},{"key":"ref7","article-title":"NexGard Combo Spot-on Solution for Cats: summary of product characteristics","year":"2021","unstructured":"NexGard Combo Spot-on Solution for Cats: summary of product characteristics. European Medicines Agency; 2021. Accessed November 14, 2025. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230824160163\/anx_160163_en.pdf"},{"key":"ref8","article-title":"New animal drug application 141-570","author":"Corrected freedom of information summary: NexGard Combo","unstructured":"Corrected freedom of information summary: NexGard Combo. New animal drug application 141-570. April 20, 2023. https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/13855"},{"issue":"3","key":"ref9","series-title":"J Vet Pharmacol Ther","first-page":"226","article-title":"Application of eprinomectin-containing parasiticides at label doses causes neurological toxicosis in cats homozygous for ABCB11930_1931del TC","volume":"47","author":"Mealey KL","year":"2024","unstructured":"Mealey KL, Burke NS, Villarino NF, Court MH, Heusser JP. Application of eprinomectin-containing parasiticides at label doses causes neurological toxicosis in cats homozygous for ABCB11930_1931del TC. J Vet Pharmacol Ther. 2024;47(3):226-230. doi:10.1111\/jvp.13431"},{"issue":"11","key":"ref10","series-title":"J Am Vet Med Assoc","first-page":"1414","article-title":"Avermectin-induced neurotoxicity and mortality reported more commonly in cats homozygous for ABCB11930_1931del TC after application of eprinomectin- versus selamectin-containing products","volume":"263","author":"Mealey KL","year":"2025","unstructured":"Mealey KL, Burke NS, Huesser J, Court MH, Cline N, Villarino NF. Avermectin-induced neurotoxicity and mortality reported more commonly in cats homozygous for ABCB11930_1931del TC after application of eprinomectin- versus selamectin-containing products. J Am Vet Med Assoc. 2025;263(11):1414-1419. doi:10.2460\/javma.25.05.0304"},{"key":"ref11","article-title":"DailyMed","author":"Revolution-selamectin solution [USA product label]","unstructured":"Revolution-selamectin solution [USA product label]. DailyMed. Accessed November 14, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8032a1ae-d192-4514-80f1-9a3b50dc2155"},{"key":"ref12","article-title":"DailyMed","author":"Revolution Plus-selamectin and sarolaner solution [USA product label]","unstructured":"Revolution Plus-selamectin and sarolaner solution [USA product label]. DailyMed. Accessed November 14, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=cbcc7b04-f3ab-4f3e-a38f-dcdc313e1b8a"},{"key":"ref13","article-title":"DailyMed","author":"Bravecto Plus-fluralaner and moxidectin solution [USA product label]","unstructured":"Bravecto Plus-fluralaner and moxidectin solution [USA product label]. DailyMed. Accessed November 14, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d9d5ebde-7ff7-4864-b393-fbe77d7a112f"},{"key":"ref14","article-title":"DailyMed","author":"Advantage Multi for Cats-imidacloprid, moxidectin solution [USA product label]","unstructured":"Advantage Multi for Cats-imidacloprid, moxidectin solution [USA product label]. DailyMed. Accessed November 14, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=4acea077-3f1a-4507-ab8c-2f65d9035c97"},{"key":"ref15","series-title":"openFDA","article-title":"Animal and veterinary API endpoints","unstructured":"US FDA. Animal and veterinary API endpoints. openFDA. Accessed November 14, 2025. https:\/\/open.fda.gov\/apis\/animalandveterinary\/event"},{"key":"ref16","article-title":"EudraVigilance Veterinary Data Warehouse","author":"European Medicines Agency","unstructured":"European Medicines Agency. EudraVigilance Veterinary Data Warehouse. Accessed November 14, 2025. https:\/\/www.adrreports.eu\/vet\/en\/search.html"},{"key":"ref17","series-title":"VICH GL24","article-title":"International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; 2007","author":"Pharmacovigilance of veterinary medicinal products: management of adverse event reports (AERs)","unstructured":"Pharmacovigilance of veterinary medicinal products: management of adverse event reports (AERs). International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; 2007. VICH GL24. Accessed November 14, 2025. https:\/\/vichsec.org\/wp-content\/uploads\/2024\/10\/GL24-st7.pdf."},{"key":"ref18","article-title":"European Medicines Agency","author":"Veterinary dictionary for drug regulatory activities (VeDDRA)","unstructured":"Veterinary dictionary for drug regulatory activities (VeDDRA). European Medicines Agency. Accessed November 14, 2025. https:\/\/www.ema.europa.eu\/en\/veterinary-regulatory-overview\/post-authorisation-veterinary-medicines\/pharmacovigilance-veterinary-medicines\/eudravigilance-veterinary#veterinary-dictionary-for-drug-regulatory-activities-veddra-11398"},{"key":"ref19","article-title":"European Medicines Agency","author":"Guidance notes on the use of VeDDRA terminology for reporting suspected adverse events in animals and humans","unstructured":"Guidance notes on the use of VeDDRA terminology for reporting suspected adverse events in animals and humans. European Medicines Agency. EMA\/CVMP\/PhVWP\/288284\/2007-Rev.17. June 12, 2025. Accessed November 14, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guidance-notes-use-veterinary-dictionary-drug-regulatory-activities-veddra-terminology-reporting-suspected-adverse-events-animals-humans-rev17_en.pdf"},{"key":"ref20","article-title":"DailyMed","author":"Profender (2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino- 2,1-aisoquinolin-4-one, emodepside solution; Profender (2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino-2,1-aisoquinolin-4-one, emodepside kit [USA Product label]","unstructured":"Profender (2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino- 2,1-aisoquinolin-4-one, emodepside solution; Profender (2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino-2,1-aisoquinolin-4-one, emodepside kit [USA Product label]. DailyMed. Accessed November 14, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=31f0a4ec-2a29-4de5-971b-633e109b276d"},{"key":"ref21","article-title":"European Medicines Agency; 2025","author":"Profender: summary of product characteristics","unstructured":"Profender: summary of product characteristics. European Medicines Agency; 2025. Accessed November 14, 2025. https:\/\/medicines.health.europa.eu\/veterinary\/en\/documents\/download\/b456ee34-5746-47f1-9727-38adc7bf5802"},{"key":"ref22","series-title":"Veterinary Pharmacovigilance: Adverse Reactions to Veterinary Medicinal Products","first-page":"231","article-title":"Pharmacovigilance in the US - an industry perspective","author":"Hodge TM","year":"2009","unstructured":"Hodge TM. Pharmacovigilance in the US - an industry perspective. In: Woodward KN, ed. Veterinary Pharmacovigilance: Adverse Reactions to Veterinary Medicinal Products. Wiley; 2009:231\u2013285."},{"issue":"5","key":"ref23","series-title":"Expert Opin Drug Saf","first-page":"929","article-title":"The role of data mining in pharmacovigilance","volume":"4","author":"Hauben M","year":"2005","unstructured":"Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929-948. doi:10.1517\/14740338.4.5.929"},{"issue":"11","key":"ref24","series-title":"Drug Saf","first-page":"981","article-title":"Perspectives on the use of data mining in pharmaco-vigilance","volume":"28","author":"Almenoff J","year":"2005","unstructured":"Almenoff J, Tonning JM, Gould AL,  Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 2005;28(11):981-1007. doi:10.2165\/00002018-200528110-00002"},{"issue":"1","key":"ref25","series-title":"J Vet Pharmacol Ther","first-page":"107","article-title":"Evaluation of signal detection algorithms within the Elanco Animal Health Pharmacovigilance database","volume":"44","author":"Novotny MJ","year":"2021","unstructured":"Novotny MJ, Rhodes A, Shields J,  Evaluation of signal detection algorithms within the Elanco Animal Health Pharmacovigilance database. J Vet Pharmacol Ther. 2021;44(1):107-115. doi:10.1111\/jvp.12909"},{"key":"ref26","article-title":"Early experience with adverse drug event signal detection and management at CVM","author":"Walter-Grimm L","unstructured":"Walter-Grimm L, Hugunin K, Palmer LA. Early experience with adverse drug event signal detection and management at CVM. Animal Health Institute Pharmacovigilance Workshop; October 25, 2016; Rockville, MD."},{"issue":"4","key":"ref27","series-title":"Eur J Clin Pharmacol","first-page":"315","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate A","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR,  A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315-321. doi:10.1007\/s002280050466"},{"issue":"6","key":"ref28","series-title":"Drug Saf","first-page":"533","article-title":"A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database","volume":"23","author":"Lindquist M","year":"2000","unstructured":"Lindquist M, St\u00e5hl M, Bate A, Edwards IR, Meyboom RHB. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533-542. doi:10.2165\/00002018-200023060-00004"},{"key":"ref29","article-title":"Signal management: current landscape and considerations for best practices","author":"Wisniewski A","year":"2020","unstructured":"Wisniewski A, Gomez A, Jokinen J,  Signal management: current landscape and considerations for best practices. TransCelerate Biopharma Inc; 2020. Accessed November 14, 2025. https:\/\/www.transceleratebiopharmainc.com\/wp-content\/uploads\/2020\/04\/TransCelerate_ASA_SignalManagementManuscript_April2020.pdf"},{"key":"ref30","article-title":"A Flexible Signal Management Framework for Animal Health Pharmacovigilance","author":"Signal Management Subcommittee of the Animal Health Institute Pharmacovigilance Working Group","year":"2024","unstructured":"Signal Management Subcommittee of the Animal Health Institute Pharmacovigilance Working Group. A Flexible Signal Management Framework for Animal Health Pharmacovigilance. Animal Health Institute; 2024. Accessed November 14, 2025. https:\/\/ahi.org\/wp-content\/uploads\/Flexible-Signal-Management-Framework_2024_FINAL.pdf"},{"key":"ref31","series-title":"J vet Pharmacol Therap","first-page":"429","article-title":"Identification of a nonsense mutation in feline ABCB1","volume":"38","author":"Mealey KL","year":"2015","unstructured":"Mealey KL, Burke NS. Identification of a nonsense mutation in feline ABCB1. J vet Pharmacol Therap. 2015;38:429-433. doi:10.1111\/jvp.12212"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/264\/5\/javma.25.10.0669.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/264\/5\/javma.25.10.0669.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/264\/5\/javma.25.10.0669.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:33:49Z","timestamp":1776436429000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/264\/5\/javma.25.10.0669.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":62,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.2460\/javma.25.10.0669","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}